var data={"title":"Ticarcillin and clavulanate potassium (United States: Not available): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ticarcillin and clavulanate potassium (United States: Not available): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7053?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Ticarcillin and clavulanate potassium (United States: Not available): Drug information&quot;</a> and <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ticarcillin and clavulanate potassium (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227693\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Timentin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050330\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Beta-lactam and Beta-lactamase Combination</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin (Antipseudomonal)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445207\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">IV: <b>Note:</b> Timentin&reg; (ticarcillin/clavulanate) is a combination product; each 3.1 g contains 3 g ticarcillin disodium and 0.1 g clavulanic acid. Dosage recommendations are based on <b>ticarcillin</b> component: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i>, 2012): IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &lt;1 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;14 days: 75 mg ticarcillin/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 15-28 days: 75 mg ticarcillin/kg/dose every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &ge;1 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 75 mg ticarcillin/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8-28 days: 75 mg ticarcillin/kg/dose every 8 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050323\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Ticarcillin and clavulanate potassium (United States: Not available): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Note:</b> Timentin&reg; (ticarcillin/clavulanate) is a combination product; each 3.1 g contains 3 g ticarcillin disodium and 0.1 g clavulanic acid. Dosage recommendations are based on <b>ticarcillin</b> component: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General  dosing, susceptible infection:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections:  200 mg ticarcillin/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b> ticarcillin/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: 300 mg ticarcillin/kg/day in divided doses every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AAP recommendations:  200-300 mg ticarcillin/kg/day in divided doses every 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum daily dose: 18 <b>g</b> ticarcillin/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis:</b> IV: 400 mg ticarcillin/kg/day in divided doses every 6 hours; higher doses have been used: 400-750  mg ticarcillin/kg/day in divided doses every 6 hours (Zobell, 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Systemic infections:</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 4-6 hours (maximum: 24 g of ticarcillin/day) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amnionitis, cholangitis, diverticulitis, endometritis, epididymo-orchitis, mastoiditis, orbital cellulitis, peritonitis, pneumonia (aspiration):</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild to moderate:</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 6 hours for 4-7 days (provided source controlled)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Liver abscess, parafascial space infections, septic thrombophlebitis:</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pseudomonas</i> infections:</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b> IV: 3.1 <b>g</b> (ticarcillin 3000 mg plus clavulanic acid 100 mg) every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment: Note:</b> Dosage recommendations are based on <b>ticarcillin</b> component:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following have been used by some clinicians (Aronoff, 2007): Dosing based on a usual dose of 200-300 ticarcillin mg/kg/day in divided doses every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR 10-29 mL/minute/1.73 m<sup>2</sup>: 50-75 mg ticarcillin/kg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> (without concomitant hepatic failure): 50-75 mg ticarcillin/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> (with concomitant hepatic failure): 50-75 mg ticarcillin/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (without concomitant hepatic failure): 50-75 mg ticarcillin/kg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (with concomitant hepatic failure): 50-75 mg ticarcillin/kg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis (without concomitant hepatic failure): 50-75 mg ticarcillin/kg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis (with concomitant hepatic failure): 50-75 mg ticarcillin/kg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 50-75 mg ticarcillin/kg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;60 mL/minute: No dosage adjustment required. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 30-60 mL/minute: 2000 mg ticarcillin component every 4 hours or 3.1 <b>g</b> (3000 mg ticarcillin component) every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 10-30 mL/minute: 2000 mg ticarcillin component every 8 hours or 3.1 <b>g</b> (3000 mg ticarcillin component) every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute without concomitant hepatic dysfunction: 2000 mg ticarcillin component every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute with concomitant hepatic dysfunction: 2000 mg ticarcillin component every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): 2000 mg of ticarcillin component every 12 hours; supplemented with 3.1 <b>g</b> (3000 mg ticarcillin component) after each dialysis session. Alternatively, administer 2000 mg of ticarcillin component every 8 hours without a supplemental dose for deep-seated infections (Heintz, 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis (PD): 3.1 <b>g</b> (3000 mg ticarcillin component) every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVH: Loading dose of 3.1 <b>g</b> (3000 mg ticarcillin component) followed by 2000 mg ticarcillin component every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVHD: Loading dose of 3.1 <b>g</b> (3000 mg ticarcillin component) followed by 3.1 <b>g</b> (3000 mg ticarcillin component) every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVHDF: Loading dose of 3.1 <b>g</b> (3000 mg ticarcillin component) followed by 3.1 <b>g</b> (3000 mg ticarcillin component) every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <b>Note:</b> Do not administer in intervals exceeding every 8 hours. Clavulanate component is hepatically eliminated; extending the dosing interval beyond 8 hours may result in loss of beta-lactamase inhibition. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVH: Dose as for CrCl 10-50 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemodialysis: 2 g every 12 hours; supplement with 3 g after each dialysis </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal Dialysis: 3 g every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing in hepatic impairment:</b> Adults: With concomitant renal dysfunction (CrCl &lt;10 mL/minute) 2000 mg ticarcillin component every 24 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51192752\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Dosage recommendations are based on <b>ticarcillin</b> component:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following have been used by some clinicians (Aronoff 2007): Dosing based on a usual dose of 200 to 300 ticarcillin mg/kg/day in divided doses every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10-29 mL/minute/1.73 m<sup>2</sup>: 50 to 75 mg ticarcillin/kg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> (without concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> (with concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (without concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (with concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (without concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (with concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 50 to 75 mg ticarcillin/kg every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220241\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no pediatric specific recommendations; based on experience in adult patients, dosing adjustment suggested with concomitant renal dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227697\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Ticarcillin and clavulanate potassium (United States: Not available): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Timentin (ticarcillin/clavulanate) is a combination product; each 3.1 g dosage form contains 3 g ticarcillin disodium and 0.1 g clavulanic acid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gynecologic infections (eg endometritis):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate infections: 200 mg ticarcillin/kg/day in divided doses every 6 hours (maximum: 12 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infections: 300 mg ticarcillin/kg/day in divided doses every 4 hours (maximum: 18 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic infections:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 200-300 mg ticarcillin/kg/day in divided doses every 4-6 hours (maximum: 18 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 kg: 3.1 g  every 4-6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 200-300 mg ticarcillin/kg/day in divided doses every 4-6 hours (maximum: 18 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 kg: 3.1 g every 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild-to-moderate (off-label use):</b> IV: 3.1 g every 6 hours for 4-7 days (provided source controlled) (Solomkin, 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990902\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loading dose: IV: 3.1 g one dose, followed by maintenance dose based on creatinine clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30-60 mL/minute: Administer 2 g of ticarcillin component every 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10-30 mL/minute: Administer 2 g of ticarcillin component every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 2 g of ticarcillin component every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute with concomitant hepatic dysfunction: 2 g of ticarcillin component every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): 2 g of ticarcillin component every 12 hours; supplemented with 3.1 g (ticarcillin/clavulanate) after each dialysis session. Alternatively, administer 2 g every 8 hours without a supplemental dose for deep-seated infections (Heintz, 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD): 3.1 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVH: Loading dose of 3.1g followed  by 2 g every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHD: Loading dose of 3.1 g followed by 3.1 g every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHDF: Loading dose of 3.1 g followed by 3.1 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Do not administer in intervals exceeding every 8 hours. Clavulanate component is hepatically eliminated; extending the dosing interval beyond 8 hours may result in loss of beta-lactamase inhibition. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988160\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">With concomitant renal dysfunction (Cl<sub>cr</sub> &lt;10 mL/minute): 2 g of ticarcillin component every 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227673\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion [premixed, frozen]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timentin: Ticarcillin 3 g and clavulanic acid 0.1 g (100 mL [DSC]) [contains sodium 4.51 mEq and potassium 0.15 mEq per g]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timentin: Ticarcillin 3 g and clavulanic acid 0.1 g (3.1 g [DSC], 31 g [DSC]) [contains sodium 4.51 mEq and potassium 0.15 mEq per g]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227657\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26640998\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050333\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer by IV intermittent infusion over 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227688\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store intact vials at &le;24&deg;C (&le;75&deg;F). Reconstituted solution is stable for 6 hours at room temperature and 72 hours when refrigerated. IV infusion in NS or LR is stable for 24 hours at room temperature (21&deg;C to 24&deg;C [70&deg;F to 75&deg;F]), 7 days when refrigerated (4&deg;C [39&deg;F]), or 30 days when frozen (-18&deg;C [0&deg;F]). IV infusion in D<sub>5</sub>W solution is stable for 24 hours at room temperature (21&deg;C to 24&deg;C [70&deg;F to 75&deg;F]), 3 days when refrigerated (4&deg;C [39&deg;F]), or 7 days when frozen (-18&deg;C [0&deg;F]. After freezing, thawed solution is stable for 8 hours at room temperature. Do not refreeze. Darkening of drug indicates loss of potency of clavulanate potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premixed solution: Store frozen at &le;-20&deg;C (-4&deg;F). Thawed solution is stable for 24 hours at room temperature (22&deg;C [72&deg;F]) or 7 days under refrigeration at (4&deg;C [39&deg;F]); do not refreeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050332\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of infections caused by susceptible organisms involving the lower respiratory tract, urinary tract,  skin and skin structures, bone and joint, gynecologic, intra-abdominal infections, and septicemia (FDA approved in ages &ge;3 months and adults). Clavulanate expands activity of ticarcillin to include beta-lactamase producing strains of <i>S. aureus</i>, <i>H. influenzae</i>, <i>Moraxella catarrhalis</i>, <i>B. fragilis</i>, <i>Klebsiella</i>, <i>Prevotella</i>, <i>P. aeruginosa</i>, <i>Stenotrophomonas maltophilia</i>, <i>E. coli</i>,  and <i>Proteus</i> species</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227720\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Local thrombophlebitis (with IV injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, drowsiness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Electrolyte disturbance, hypernatremia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: <i>Clostridium difficile</i> diarrhea, diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Proteinuria (false positive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Bleeding complication, eosinophilia, hemolytic anemia, positive direct Coombs' test (false positive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatotoxicity, increased serum ALT, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Jarisch Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Superinfection (fungal or bacterial)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Interstitial nephritis (acute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Altered sense of smell, chest discomfort, chills, decreased hematocrit, decreased hemoglobin, decreased serum potassium, dizziness, dysgeusia, erythema multiforme, flatulence, headache, hemorrhagic cystitis, hypersensitivity reaction, hypouricemia, increased blood urea nitrogen, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum creatinine, injection site reaction (burning, induration, pain, swelling), leukopenia, myalgia, myoclonus, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis (during or after antibacterial treatment), Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227680\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (history of a serious reaction [eg, anaphylaxis, Stevens-Johnson syndrome]) to ticarcillin, clavulanate, or to other beta-lactams (eg, penicillins, cephalosporins)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227661\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concern related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Particularly in patients with renal impairment, bleeding disorders have been observed; discontinue if thrombocytopenia or bleeding occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypokalemia: Hypokalemia has been reported; monitor serum potassium in patients with fluid and electrolyte imbalance and in patients receiving prolonged therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Use with caution in patients with HF, due to high sodium load.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300140\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227666\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12843&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227669\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4812151\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Ticarcillin and clavulanate cross the placenta (Maberry, 1992). Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects (Crider, 2009; Santos, 2011). Ticarcillin/clavulanate is approved for the treatment of postpartum gynecologic infections, including endometritis, caused by susceptible organisms. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050329\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, periodic renal, hepatic and hematologic function tests; observe IV injection site for signs of extravasation; observe for signs and symptoms of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227660\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227679\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Ticarcillin is distributed into tissue, interstitial fluid, pleural fluid, and bile; low concentrations of ticarcillin distribute into the CSF but increase when meninges are inflamed; V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ticarcillin: 0.22 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clavulanic acid: 0.4 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Ticarcillin: ~45%; Clavulanic acid: ~25% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Clavulanic acid is metabolized hepatically </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: Ticarcillin: 4.4 hours; Clavulanic acid: 1.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (1 month to 9.3 years): Ticarcillin: 66 minutes; Clavulanic acid: 54 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Ticarcillin: 66 to 72 minutes; 13 hours (in patients with renal failure); Clavulanic acid: 66 to 90 minutes; clavulanic acid does not affect the clearance of ticarcillin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Immediately following completion of 30-minute infusion </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Ticarcillin: Urine (71%  50% as unchanged drug over 4 hour); Clavulanic acid: Urine (50% as unchanged drug over 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Ticarcillin: Urine (60% to 70% as unchanged drug); Clavulanic acid: Urine (35% to 45% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323972\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Timentin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">31 g (1): $159.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227683\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betabactyl (DE);</li>\n      <li>Claventin (FR);</li>\n      <li>Ticarcin (PH);</li>\n      <li>Ticarnic (LK);</li>\n      <li>Timentin (AE, AU, BE, BF, BH, BJ, BR, CI, CN, CY, CZ, EG, ET, GB, GH, GM, GN, GR, HK, ID, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LK, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NZ, OM, PE, PL, QA, RO, RU, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UA, UG, VN, YE, ZA, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Begue P, Quiniou F, Quinet B, &ldquo;Efficacy and Pharmacokinetics of Timentin&reg; in Paediatric Infections,&rdquo; <i>J Antimicrob Chemother</i>, 1986, 17(Suppl C):81-91. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/3636339/pubmed\" target=\"_blank\" id=\"3636339\">3636339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricke G, Doerck M, Hafner D, et al, &quot;The Pharmacokinetics of Ticarcillin/Clavulanate Acid in Neonates,&quot; <i>J Antimicrob Chemother</i>, 1989, 24(Suppl B):111-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/2606813/pubmed\" target=\"_blank\" id=\"2606813\">2606813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>, 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Yamashita TS, and Blumer JL, &ldquo;Pharmacokinetic-Based Ticarcillin/Clavulanic Acid Dose Recommendations for Infants and Children,&rdquo; <i>J Clin Pharmacol</i>, 1995, 35(7):658-65. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/7560245/pubmed\" target=\"_blank\" id=\"7560245\">7560245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al, &quot;Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins,&quot; <i>Pediatr Pulmonol</i>, 2013, 48(2):107-22. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ticarcillin-and-clavulanate-potassium-united-states-not-available-pediatric-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12843 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F227693\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050330\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445207\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1050323\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51192752\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51220241\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F227697\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990902\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988160\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F227673\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F227657\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F26640998\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050333\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F227688\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050332\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227720\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227680\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227661\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300140\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227666\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227669\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4812151\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050329\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227660\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F227679\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323972\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F227683\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12843|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">Ticarcillin and clavulanate potassium (United States: Not available): Drug information</a></li><li><a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Ticarcillin and clavulanate potassium (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}